What is B. Riley’s Estimate for Geron FY2027 Earnings?

Geron Co. (NASDAQ:GERN) – Stock analysts at B. Riley decreased their FY2027 EPS estimates for shares of Geron in a note issued to investors on Tuesday, February 18th. B. Riley analyst K. Patel now expects that the biopharmaceutical company will earn $0.28 per share for the year, down from their prior forecast of $0.36. B. Riley currently has a “Buy” rating and a $3.50 target price on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

GERN has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Geron in a research note on Tuesday, December 10th. Barclays raised shares of Geron to a “strong-buy” rating in a report on Friday, November 29th. Finally, Needham & Company LLC upped their target price on shares of Geron from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.91.

Geron Price Performance

Geron stock opened at $2.63 on Wednesday. The firm has a 50-day moving average of $3.19 and a 200-day moving average of $3.90. Geron has a one year low of $1.64 and a one year high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. SBI Securities Co. Ltd. bought a new position in Geron in the 4th quarter valued at about $28,000. Integrated Wealth Concepts LLC bought a new position in Geron in the 4th quarter valued at about $36,000. GF Fund Management CO. LTD. bought a new position in Geron in the 4th quarter valued at about $45,000. Fifth Lane Capital LP bought a new position in Geron in the 4th quarter valued at about $53,000. Finally, Readystate Asset Management LP bought a new position in shares of Geron during the third quarter worth approximately $58,000. 73.71% of the stock is owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.